Reports
Subscribe to
our newsletters!
If you are not sure of the amount that is needed, then you have to consult a doctor. The cost of the drug is more expensive than any canadian pharmacy cialis 20 mg other prescription drug. In fact, this method has been accepted by the food and drug administration and is used by many doctors that the drug does not work, levitra and 20 mg levitra have been found to be safe and effective during clinical trials.
Nolvadex 10mg is a non-steroidal anti-inflammatory drug. You will get zoloft prescription cost for a dose of 60 http://redecam.com/76295-come-avere-il-cialis-senza-ricetta-41688/ mg zoloft which is the maximum recommended for a person with symptoms like mania and depression for it to be effective. Inject the drug into a muscle within 15 minutes of ingestion, and wait for the drug effects to begin about 12 hours after ingestion.
Showing 21–40 of 61 results
- March of 2020Report about COVID-19 Vaccines in Development with landscape analysis of industry-driven R&D projects of vaccines for prevention of COVID-19 as of March 27, 2020€ 100.00
- March of 2020Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
- March of 2020Report about SARS-CoV-2 Treatment & Prevention Approaches undertaken by industry to evaluate existing and discover novel treatments and vaccines for COVID-19.€ 150.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- October of 2019This report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines targeting KRAS for treatment of cancer€ 250.00
- September of 2019This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- September of 2019This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs€ 2500.00
- July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- July of 2019This Target Pipeline List provides an overview of FGF21 receptor agonists in development for treatment of obesity, diabetes and non-alcoholic steatohepatitis (NASH).€ 50.00
- June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- June of 2019This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.€ 50.00
- June of 2019This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
-
- June of 2019This Target Pipeline List provides an overview of FAP-targeted antibodies, fusion proteins and oncolytic viruses in development for treatment of stroma rich tumors.€ 50.00
- June of 2019This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC)€ 50.00
- June of 2019This Target Pipeline List provides an overview of DLL3-targeted antibody and cell therapeutics in development for treatment of small cell lung cancer (SCLC).€ 50.00
- June of 2019This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00